Advertisement

Atlas and Anatomy of PET/CT

  • E. Edmund Kim
  • Hyung-Jun Im
  • Dong Soo Lee
  • Keon Wook Kang
Chapter

Abstract

PET-CT is a combined system of the positron emission tomography (PET) and computed tomography (CT) scanner, which enables co-registered images from both devices. By PET-CT, functional imaging obtained by PET, which shows metabolic or biochemical activity in the body, can be correlated with the anatomic imaging obtained by a CT scanner. PET-CT has revolutionized medical diagnosis by adding the precision of anatomic localization to functional imaging. Many diagnostic imaging procedures in oncology (e.g., cancer staging, surgical planning, radiation therapy) and neurology (Alzheimer disease, Parkinson disease) have been changed rapidly under the influence of PET-CT availability. In this chapter, oncologic PET/CT cases are mainly covered. The cases are presented in multiple slices with annotation of important structures. The first part of this chapter consists of fludeoxyglucose (FDG) PET/CT cases, and the second part consists of non-FDG PET/CT cases. In the non-FDG PET/CT portion, several neurologic application of PET/CT are included.

Keywords

PET/CT, FDG Non-FDG Oncology Anatomy 

References

  1. 1.
    Chung J-K, Kim Y, Kim S-K, Lee Y, Paek S, Yeo J et al (2002) Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging 29:176–82CrossRefPubMedGoogle Scholar
  2. 2.
    Paidpally V, Tahari AK, Lam S, Alluri K, Marur S, Koch W et al (2013) Addition of 18F-FDG PET/CT to clinical assessment predicts overall survival in HNSCC: a retrospective analysis with follow-up for 12 years. J Nucl Med 54:2039–45CrossRefPubMedGoogle Scholar
  3. 3.
    Acar T, Savas R, Kocacelebi K, Guneyli S (2014) Supraclavicular lymphadenopathy: should it be perceived as the Virchow’s node of head and neck tumors? Oncol Res Treat 37:726–30CrossRefPubMedGoogle Scholar
  4. 4.
    Joo YH, Yoo IR, Cho KJ, Park JO, Nam IC, Kim CS et al (2014) The value of preoperative 18F‐FDG PET/CT for assessing the contralateral neck in head and neck cancer patients with unilateral node metastasis (N1‐3). Clin Otolaryngol 39:338–44CrossRefPubMedGoogle Scholar
  5. 5.
    Arya S, Rane P, Deshmukh A (2014) Oral cavity squamous cell carcinoma: role of pretreatment imaging and its influence on management. Clin Radiol 69:916–30CrossRefPubMedGoogle Scholar
  6. 6.
    Rosen EL, Eubank WB, Mankoff DA (2007) FDG PET, PET/CT, and breast cancer imaging 1. Radiographics 27:S215–9CrossRefPubMedGoogle Scholar
  7. 7.
    Gaeta C, Vercher-Conejero J, Sher A, Kohan A, Rubbert C, Avril N (2013) Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers. Q J Nucl Med Mol Imaging 57:352–66PubMedGoogle Scholar
  8. 8.
    Lu Y-Y, Chen J-H, Liang J-A, Chu S, Lin W-Y, Kao C-H (2014) 18F-FDG PET or PET/CT for detecting extensive disease in small-cell lung cancer: a systematic review and meta-analysis. Nucl Med Commun 35:697–703CrossRefPubMedGoogle Scholar
  9. 9.
    Antoniou AJ, Marcus C, Tahari AK, Wahl RL, Subramaniam RM (2014) Follow-up or surveillance 18F-FDG PET/CT and survival outcome in lung cancer patients. J Nucl Med 55:1062–8CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Heusch P, Buchbender C, Köhler J, Nensa F, Gauler T, Gomez B et al (2014) Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT. J Nucl Med 55:373–8CrossRefPubMedGoogle Scholar
  11. 11.
    De Wever W, Verschakelen J, Coolen J (2014) Role of imaging in diagnosis, staging and follow-up of lung cancer. Curr Opin Pulm Med 20:385–92CrossRefPubMedGoogle Scholar
  12. 12.
    Hayes SA, Plodkowski AJ, Ginsberg MS (2014) Imaging of thoracic cavity tumors. Surg Oncl Clin N Am 23:709–33CrossRefGoogle Scholar
  13. 13.
    Prabhakar HB, Rabinowitz CB, Gibbons FK, O'Donnell WJ, Shepard J-AO, Aquino SL (2008) Imaging features of sarcoidosis on MDCT, FDG PET, and PET/CT. Am J Roentgenol 190(3 Suppl):S1–6CrossRefGoogle Scholar
  14. 14.
    Soussan M, Augier A, Brillet P-Y, Weinmann P, Valeyre D (2014) Functional imaging in extrapulmonary sarcoidosis: FDG-PET/CT and MR features. Clin Nucl Med 39:e146–59PubMedGoogle Scholar
  15. 15.
    Al-Thani H, El-Menyar A, Rasul KI, Al-Sulaiti M, El-Mabrok J, Hajaji K et al (2014) Clinical presentation, management and outcomes of gastrointestinal stromal tumors. Int J Surg 12:1127–33CrossRefPubMedGoogle Scholar
  16. 16.
    Kim HO, Kim JE, Bae KS, Choi BH, Jeong CY, Lee JS (2014) Imaging findings of primary malignant gastrointestinal stromal tumor of the liver. Jpn J Radiol 32:365–70CrossRefPubMedGoogle Scholar
  17. 17.
    Shulkin BL, Chang E, Strouse PJ, Bloom DA, Hutchinson RJ (1997) PET FDG studies of Wilms tumors. J Pediatr Hematol Oncol 19:334–8CrossRefPubMedGoogle Scholar
  18. 18.
    Hossain AM, Shulkin BL, Gelfand MJ, Bashir H, Daw NC, Sharp SE et al (2010) FDG positron emission tomography/computed tomography studies of Wilms’ tumor. Eur J Nucl Med Mol Imaging 37:1300–8CrossRefGoogle Scholar
  19. 19.
    Park K, Jang G, Baek S, Song H (2013) Usefulness of combined PET/CT to assess regional lymph node involvement in gastric cancer. Tumori 100:201–6Google Scholar
  20. 20.
    Yun M (2014) Imaging of gastric cancer metabolism using 18F-FDG PET/CT. J Gastric Cancer 14:1–6CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Ma Q, Xin J, Zhao Z, Guo Q, Yu S, Xu W et al (2013) Value of 18F-FDG PET/CT in the diagnosis of primary gastric cancer via stomach distension. Eur J Radiol 82:e302–6CrossRefPubMedGoogle Scholar
  22. 22.
    Chung HW, Lee S-Y, Han HS, Park HS, Yang JH, Lee HH et al (2013) Gastric cancers with microsatellite instability exhibit high fluorodeoxyglucose uptake on positron emission tomography. Gastric Cancer 16:185–92CrossRefPubMedGoogle Scholar
  23. 23.
    Rijkers A, Valkema R, Duivenvoorden H, van Eijck C (2014) Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer: a meta-analysis. Eur J Surg Oncol 40:794–804CrossRefPubMedGoogle Scholar
  24. 24.
    Strobel K, Heinrich S, Bhure U, Soyka J, Veit-Haibach P, Pestalozzi BC et al (2008) Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer. J Nucl Med 49:1408–13CrossRefPubMedGoogle Scholar
  25. 25.
    Epelbaum R, Frenkel A, Haddad R, Sikorski N, Strauss LG, Israel O et al (2013) Tumor aggressiveness and patient outcome in cancer of the pancreas assessed by dynamic 18F-FDG PET/CT. J Nucl Med 54:12–8CrossRefPubMedGoogle Scholar
  26. 26.
    Heinrich S, Goerres GW, Schäfer M, Sagmeister M, Bauerfeind P, Pestalozzi BC et al (2005) Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 242:235CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Tsurusaki M, Okada M, Kuroda H, Matsuki M, Ishii K, Murakami T (2014) Clinical application of 18F-fluorodeoxyglucose positron emission tomography for assessment and evaluation after therapy for malignant hepatic tumor. J Gastroenterol 49:46–56CrossRefPubMedGoogle Scholar
  28. 28.
    Song MJ, Bae SH, Lee SW, Kim HY, Yoo IR, Choi J-I et al (2013) 18F-fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 40:865–73CrossRefPubMedGoogle Scholar
  29. 29.
    Talbot J-N, Fartoux L, Balogova S, Nataf V, Kerrou K, Gutman F et al (2010) Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. J Nucl Med 51:1699–706CrossRefPubMedGoogle Scholar
  30. 30.
    Schierz J-H, Opfermann T, Steenbeck J, Lopatta E, Settmacher U, Stallmach A et al (2013) Early dynamic 18F-FDG PET to detect hyperperfusion in hepatocellular carcinoma liver lesions. J Nucl Med 54:848–54CrossRefPubMedGoogle Scholar
  31. 31.
    Sun L, Guan Y-S, Pan W-M, Luo Z-M, Wei J-H, Zhao L et al (2009) Metabolic restaging of hepatocellular carcinoma using whole-body 18F-FDG PET/CT. World J Hepatol 1:90CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Kijima S, Sasaki T, Nagata K, Utano K, Lefor AT, Sugimoto H (2014) Preoperative evaluation of colorectal cancer using CT colonography, MRI, and PET/CT. World J Gastroenterol 20:16964–74CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Engelmann BE, Loft A, Kjær A, Nielsen HJ, Gerds TA, Benzon EV et al (2014) Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer. Oncologist 19:164–72CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Bipat S, Niekel M, Comans E, Nio C, Bemelman W, Verhoef C et al (2012) Imaging modalities for the staging of patients with colorectal cancer. Neth J Med 70:26–34PubMedGoogle Scholar
  35. 35.
    Brush J, Boyd K, Chappell F, Crawford F, Dozier M, Fenwick E et al (2011) The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation. Health Technol Assess 15:1–192CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Grassetto G, Capirci C, Marzola MC, Rampin L, Chondrogiannis S, Musto A et al (2012) Colorectal cancer: prognostic role of 18F-FDG-PET/CT. Abdom Imaging 37:575–9CrossRefPubMedGoogle Scholar
  37. 37.
    Metser U, Hussey D, Murphy G (2014) Impact of 18F-FDG PET/CT on the staging and management of follicular lymphoma. Br J Radiol 87:1042CrossRefGoogle Scholar
  38. 38.
    Gallamini A, Borra A (2014) Role of PET in lymphoma. Curr Treat Options Oncol 15:248–61CrossRefPubMedGoogle Scholar
  39. 39.
    Chavdarova LI, Tzonevska AD, Piperkova EN (2012) Discrepancies and priorities in staging and restaging malignant lymphoma by SPET, SPET/CT, PET/CT and PET/MRI. Hell J Nucl Med 16:223–9Google Scholar
  40. 40.
    Le Dortz L, De Guibert S, Bayat S, Devillers A, Houot R, Rolland Y et al (2010) Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging 37:2307–14CrossRefPubMedGoogle Scholar
  41. 41.
    Quartuccio N, Fox J, Kuk D, Wexler LH, Baldari S, Cistaro A et al (2015) Pediatric bone sarcoma: diagnostic performance of 18F-FDG PET/CT versus conventional imaging for initial staging and follow-up. Am J Roentgenol 204:153–60CrossRefGoogle Scholar
  42. 42.
    Costelloe CM, Chuang HH, Madewell JE (2014) FDG PET/CT of primary bone tumors. Am J Roentgenol 202:W521–31CrossRefGoogle Scholar
  43. 43.
    Quartuccio N, Treglia G, Salsano M, Mattoli MV, Muoio B, Piccardo A et al (2013) The role of Fluorine-18-Fluorodeoxyglucose positron emission tomography in staging and restaging of patients with osteosarcoma. Radiol Oncol 47:97–183CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Walter F, Federman N, Apichairuk W, Nelson S, Phelps ME, Allen-Auerbach M et al (2011) 18F-fluorodeoxyglucose uptake of bone and soft tissue sarcomas in pediatric patients. Pediatr Hematol Oncol 28:579–87CrossRefPubMedGoogle Scholar
  45. 45.
    Charest M, Hickeson M, Lisbona R, Novales-Diaz J-A, Derbekyan V, Turcotte RE (2009) FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases. Eur J Nucl Med Mol Imaging 36:1944–51CrossRefPubMedGoogle Scholar
  46. 46.
    Fuglø HM, Jørgensen SM, Loft A, Hovgaard D, Petersen MM (2012) The diagnostic and prognostic value of 18F-FDG PET/CT in the initial assessment of high-grade bone and soft tissue sarcoma: a retrospective study of 89 patients. Eur J Nucl Med Mol Imaging 39:1416–24CrossRefPubMedGoogle Scholar
  47. 47.
    Oyama N, Okazawa H, Kusukawa N, Kaneda T, Miwa Y, Akino H et al (2009) 11C-Acetate PET imaging for renal cell carcinoma. Eur J Nucl Med Mol Imaging 36:422–7CrossRefPubMedGoogle Scholar
  48. 48.
    Grassi I, Nanni C, Allegri V, Morigi JJ, Montini GC, Castellucci P et al (2012) The clinical use of PET with (11)C-acetate. Am J Nucl Med Mol Imaging 2:33–47PubMedGoogle Scholar
  49. 49.
    Higashi K, Ueda Y, Matsunari I, Kodama Y, Ikeda R, Miura K et al (2004) 11C-acetate PET imaging of lung cancer: comparison with 18F-FDG PET and 99mTc-MIBI SPET. Eur J Nucl Med Mol Imaging 31:13–21CrossRefPubMedGoogle Scholar
  50. 50.
    Ogawa T, Shishido F, Kanno I, Inugami A, Fujita H, Murakami M et al (1993) Cerebral glioma: evaluation with methionine PET. Radiology 186:45–53CrossRefPubMedGoogle Scholar
  51. 51.
    Singhal T, Narayanan TK, Jacobs MP, Bal C, Mantil JC (2012) 11C-Methionine PET for grading and prognostication in gliomas: a comparison study with 18F-FDG PET and contrast enhancement on MRI. J Nucl Med 53:1709–15CrossRefPubMedGoogle Scholar
  52. 52.
    Kato T, Shinoda J, Nakayama N, Miwa K, Okumura A, Yano H et al (2008) Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography. Am J Neuroradiol 29:1176–82CrossRefPubMedGoogle Scholar
  53. 53.
    Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND et al (2008) Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain 131(Pt 6):1630–45CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Zhang S, Smailagic N, Hyde C, Noel-Storr AH, Takwoingi Y, McShane R et al (2014) (11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 7:CD010386PubMedGoogle Scholar
  55. 55.
    Cohen AD, Klunk WE. Early detection of Alzheimer’s disease using PiB and FDG PET. Neurobiol Dis. 2014;72, Part A(0):117–22.Google Scholar
  56. 56.
    Wang J, Zuo C-T, Jiang Y-P, Guan Y-H, Chen Z-P, Xiang J-D et al (2007) 18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson’s disease in various Hoehn & Yahr stages. J Neurol 254:185–90CrossRefPubMedGoogle Scholar
  57. 57.
    Song I-U, Chung Y-A, Oh J-K, Chung S-W (2014) An FP-CIT PET comparison of the difference in dopaminergic neuronal loss in subtypes of early Parkinson’s disease. Acta Radiol 55:366–71CrossRefPubMedGoogle Scholar
  58. 58.
    Lorberboym M, Treves TA, Melamed E, Lampl Y, Hellmann M, Djaldetti R (2006) [123I]‐FP/CIT SPECT imaging for distinguishing drug‐induced parkinsonism from Parkinson’s disease. Mov Disord 21:510–14CrossRefPubMedGoogle Scholar
  59. 59.
    Yoon H-J, Kang K, Chun I, Cho N, Im S-A, Jeong S et al (2014) Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from 68Ga-RGD PET/CT and 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging 41:1534–43CrossRefPubMedGoogle Scholar
  60. 60.
    Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL et al (2006) Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin αvβ3 expression in man. Clin Cancer Res 12:3942–9CrossRefPubMedGoogle Scholar
  61. 61.
    Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B et al (2013) 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT. Eur J Nucl Med Mol Imaging 40:514–23CrossRefPubMedGoogle Scholar
  62. 62.
    Oh J-R, Kulkarni H, Carreras C, Schalch G, Min J-J, Baum RP (2012) Ga-68 Somatostatin receptor PET/CT in von Hippel-Lindau disease. Nucl Med Mol Imaging 46:129–33CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • E. Edmund Kim
    • 1
  • Hyung-Jun Im
    • 2
  • Dong Soo Lee
    • 1
    • 3
  • Keon Wook Kang
    • 4
  1. 1.Department of Radiological SciencesSchool of Medicine, University of California at IrvineIrvineUSA
  2. 2.Department of Nuclear MedicineSeoul National UniversitySeoulRepublic of Korea
  3. 3.Department of Nuclear Medicine and Department of Molecular Medicine and Biopharmaceutical SciencesSeoul National UniversitySeoulRepublic of Korea
  4. 4.Department of Nuclear Medicine and Cancer Research InstituteSeoul National UniversitySeoulRepublic of Korea

Personalised recommendations